Search

The article presents a formulary drug review on Defibrotide, a noted hematological agent. Discussed is the drug's indication, clinical pharmacology, pharmacokinetics, adverse reactions, contraindications, warnings and precautions. Also highlighted are recommended monitoring, safety and risk evaluation and mitigation strategy (REMS) of the Defibrotide.

The article presents review of Doxylamine Succinate/Pyridoxine HydrochlorideDelayed-ReleaseTablets also known as Diclegis which are being manufactured by Duchesnay Inc. It mentions that that the drug has been approved to be used in pregnant women for treatment of vomiting and nausea but the drug has not been still approved for the treatment of hyperemesis gravidarum. It reports on clinical pharmacology, pharmacokinetics, and warning and precautions associated with Diclegis.

The article discusses the efficiency of tofacitinib in patients with rheumatoid arthritis (RA) with adequate response to methotrexate (MTX). The article provides two comparative studies to evaluate the safety of tofacitinib therapy for the treatment of RA with long-use monotherapy, and concomitant nonbiologic disease-modifying antirheumatic drug (DMARD) therapy. It concludes that tofacitinib is a useful for the treatment of some patients with RA who are receiving background methotrexate.

The article discusses Lucinactant which is a synthetic, exogenous surfactant approved only for the prevention of Respiratory distress syndrome (RDS) in high-risk premature infants. The data demonstrates a reduction in the development of RDS and mortality rates related to RDS in premature infants. Lucinactant provides a consistent, reproducible manufactured product free from an increased risk of immunogenicity which is resistant to degradation and endogenous concentrations.

The article discusses Ivermectin 0.5% Topical Lotion, which is indicated for the topical treatment of head lice infestation in patients 6 months or older. The topical lotion exhibits pediculicidal activity and is not directly ovicidal. The various pediculicidal and scabicidal agents approved by the U.S. Food and Drug Administration (FDA) are included. Studies evaluating the comparative efficacy of Ivermectin are described. The contraindications, warnings and precautions to be taken are included.

The article offers formulary drug review on drug Ivacaftor. It mentions drug indications, clinical pharmacology, comparative efficacy and pharmacokinetics. It states that The US Food and Drug Administration (FDA) approved labeling lists no contraindications to therapy with Ivacaftor. It mentions the drug's adverse reactions, drug interactions, dosing, product availability and storage. It suggests that the use of Ivacaftor must be limited to patients with the G551D mutation.

The article offers information on glucarpidase drug, including its indications, efficacy, and adverse reactions. It says that glucarpidase is being indicated to treat toxic plasma methotrexate concentrations in renal function impaired patients. It states the adverse reactions of glucarpidase in various diseases, including paresthesias, headache, and nausea. It also discusses various studies which examine the comparative efficacy of the drug.

The article offers information on the drug Aflibercept including its indications, clinical pharmacology, and pharmacokinetics. It says that the drug is used for the treatment of the wet age-related mascular degeneration. It says that the drug is given through intravitreal injection. Among the contraindications to the drug's use are hypersensitivity, active ocular or periocular infection, and severe intraocular inflammation.